Advertisement

This site uses cookies to enhance your user experience. By continuing to use this site you are agreeing to our COOKIE POLICY.

ACCEPT AND CLOSE

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

The key to knowledge is in your (nitrile-gloved) hands

Already an ACS Member?  

Basic

$0 Community Associate

ACS’s Basic Package keeps you connected with C&EN and ACS.

  • Access to 6 digital C&EN articles per month on cen.acs.org
  • Weekly delivery of the C&EN Essential newsletter
JOIN NOW
Standard

$80 Regular Members & Society Affiliates

ACS’s Standard Package lets you stay up to date with C&EN, stay active in ACS, and save.

Eligibility restrictions apply. Review ACS Membership Packages to see if you qualify.

JOIN NOW
Premium

$160 Regular Members & Society Affiliates
$55 Graduate Students
$25 Undergraduate Students

ACS’s Premium Package gives you full access to C&EN and everything the ACS Community has to offer.

  • Unlimited access to C&EN’s daily news coverage on cen.acs.org
  • Weekly delivery of the C&EN Magazine in print or digital format
  • Access to our Chemistry News by C&EN mobile app
  • Significant discounts on registration for most ACS-sponsored meetings
ACS offers discounts for some countries outside the United States. This discount is shown at checkout, if applicable.

JOIN NOW

Thank you!

Your account has been created successfully, and a confirmation email is on the way.

Your username is now your ACS ID.

ENJOY UNLIMITED ACCES TO C&EN

People

Mikael Dolsten, Pfizer’s top scientist, to step down

by Rowan Walrath
July 11, 2024 | A version of this story appeared in Volume 102, Issue 21
Advertisement

Most Popular in People

 

Pfizer’s chief scientific officer, Mikael Dolsten, is slated to depart after 15 years at the drug giant. Dolsten will remain in the role while a successor is identified, which Pfizer says could take until early 2025. Dolsten joined Pfizer when it acquired Wyeth in 2009. He was promoted to the executive suite shortly after and went on to oversee the approval of more than 35 drugs and vaccines, including Pfizer’s vaccine and therapy for COVID-19. Dolsten has not indicated his next move but wrote on LinkedIn that he wants to “contribute to the next wave of breakthroughs in exciting, new ways.”

Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society

You might also like...

Serving the chemical, life science, and laboratory worlds
Obituaries
Andrew Streitwieser
Serving the chemical, life science, and laboratory worlds
Obituaries
James C. Fanning
Serving the chemical, life science, and laboratory worlds
Obituaries
Frank A. L. Anet

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.
GET MORE
GET MORE